{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:58:25Z","timestamp":1780412305821,"version":"3.54.1"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Fund for Scientific Research Flanders","award":["G.0804.11N"],"award-info":[{"award-number":["G.0804.11N"]}]},{"name":"Fund for Scientific Research Flanders","award":["WO.026.11N"],"award-info":[{"award-number":["WO.026.11N"]}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            In this study, we investigated the potential antifungal activity of the alkylphospholipid oleylphosphocholine (OlPC), a structural analogue of miltefosine, on\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            <jats:named-content content-type=\"genus-species\">Candida albicans<\/jats:named-content>\n            biofilm formation. The effect of OlPC on\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            biofilms inside triple-lumen polyurethane catheters was studied.\n            <jats:italic>In vivo<\/jats:italic>\n            biofilms were developed subcutaneously after catheter implantation on the lower back of Sprague-Dawley rats. Animals were treated orally with OlPC (20 mg\/kg of body weight\/day) for 7 days. The effect of OlPC on biofilms that developed on the mucosal surface was studied in an\n            <jats:italic>ex vivo<\/jats:italic>\n            model of oral candidiasis. The role of OlPC in\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            morphogenesis was investigated by using hypha-inducing media, namely, Lee, Spider, and RPMI 1640 media. OlPC displayed activity against both planktonic cells and\n            <jats:italic>in vitro<\/jats:italic>\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            biofilms. To completely abolish preformed, 24-h-old biofilms, higher concentrations (8, 10, and 13 mg\/liter) were needed. Moreover, OlPC was able to reduce\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            biofilms formed by caspofungin-resistant clinical isolates and acted synergistically when combined with caspofungin. The daily oral administration of OlPC significantly reduced\n            <jats:italic>in vivo<\/jats:italic>\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            biofilms that developed subcutaneously. In addition, OlPC decreased biofilm formation on mucosal surfaces. Interestingly, the application of subinhibitory concentrations of OlPC already inhibited the yeast-to-hypha transition, a crucial virulence factor of\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            . We document, for the first time, the effects of OlPC on\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            cells and suggest the potential use of OlPC for the treatment of\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            biofilm-associated infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01767-17","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:40:25Z","timestamp":1508805625000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Antifungal Activity of Oleylphosphocholine on\n            <i>In Vitro<\/i>\n            and\n            <i>In Vivo Candida albicans<\/i>\n            Biofilms"],"prefix":"10.1128","volume":"62","author":[{"given":"Michelle","family":"Holtappels","sequence":"first","affiliation":[{"name":"KU Leuven, Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, Heverlee-Leuven, Belgium"},{"name":"VIB-KU Leuven, Center for Microbiology, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Swinnen","sequence":"additional","affiliation":[{"name":"KU Leuven, Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, Heverlee-Leuven, Belgium"},{"name":"VIB-KU Leuven, Center for Microbiology, Flanders, Belgium"},{"name":"Department of Biology, Functional Biology, KU Leuven, Heverlee-Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lies","family":"De Groef","sequence":"additional","affiliation":[{"name":"Laboratory of Neural Circuit Development and Regeneration, Animal Physiology and Neurobiology Section, Department of Biology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Wuyts","sequence":"additional","affiliation":[{"name":"KU Leuven, Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, Heverlee-Leuven, Belgium"},{"name":"VIB-KU Leuven, Center for Microbiology, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Moons","sequence":"additional","affiliation":[{"name":"Laboratory of Neural Circuit Development and Regeneration, Animal Physiology and Neurobiology Section, Department of Biology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-897X","authenticated-orcid":false,"given":"Patrick","family":"Van Dijck","sequence":"additional","affiliation":[{"name":"KU Leuven, Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, Heverlee-Leuven, Belgium"},{"name":"VIB-KU Leuven, Center for Microbiology, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So\u0148a","family":"Kuchar\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"KU Leuven, Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, Heverlee-Leuven, Belgium"},{"name":"VIB-KU Leuven, Center for Microbiology, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MB-0020-2015"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftw018"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12831"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp429"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01890-15"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.010"},{"key":"e_1_3_3_8_2","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar S","year":"2007","unstructured":"Sundar S, Olliaro PL. 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3:733\u2013740.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks273"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-013-3638-2"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003144"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12286"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00973"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2011.585606"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00697-10"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02288-12"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01162-08"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.13.101"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.033530-0"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2096-9"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.072322"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2013.08.004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2014.04.003"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005133"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00328721"},{"key":"e_1_3_3_26_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement M27-S4","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement M27-S4. CLSI, Wayne, PA."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1567-1364.2010.00632.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7992058"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/00362177585190271"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01767-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01767-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:09:50Z","timestamp":1645477790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01767-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1128\/AAC.01767-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01767-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"2017-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01767-17"}}